Clinical Trials Insight: 700032156
Phase of Trial: Phase III
Latest Information Update: 29 Apr 2009
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors NeoPharm Inc
- 29 Apr 2009 Status changed from planning to discontinued. Regulary approval has not been granted by the Directorate General of Health Services - Office of Drugs Controller General (India). DCGI requested concurrent enrolment of patients in the trial in the USA.
- 13 May 2008 IND submission expected olate 2008.
- 03 Apr 2008 New trial record.